NCT01156701View on ClinicalTrials.gov

Prophylactic Efficacy of Relenza Against Influenza A and B

CompletedOBSERVATIONAL
Enrollment

171,705

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Pulmonary Disease, Chronic ObstructiveBronchospasmInfluenza, HumanAsthmaRespiratory DiseaseExacerbation of COPDBronchitisOtitis MaediaPneumoniaSinusitis
Interventions
DRUG

Receiving a prescription of Relenza for prophylaxis

Receiving a prescription of Relenza for prophylaxis

OTHER

No prophylaxis with Relenza

No prophylaxis with Relenza

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01156701 - Prophylactic Efficacy of Relenza Against Influenza A and B | Biotech Hunter | Biotech Hunter